▁III ▁trial ▁( the ▁BO RE AL IS - AF ▁study ), ▁id rab iot ap arin ux ▁sod ium ▁was ▁non - in fer ior ▁to ▁war far in ▁in ▁prevent ing ▁the ▁rec urrent ▁ven ous ▁th rom bo emb ol ism ▁at ▁three ▁months ▁in ▁patients ▁with ▁pul mon ary ▁em bol ism ▁and ▁the ▁inc idence ▁of ▁clin ically ▁relevant ▁ble eding ▁was ▁lower ▁in ▁the ▁id rab iot ap arin ux ▁sod ium ▁arm . ▁The ▁drug ▁was ▁expected ▁to ▁be ▁file d ▁for ▁stroke ▁prevent ion ▁in ▁patients ▁with ▁at rial ▁f ibr ill ation ▁in ▁ 2 0 1 1 . ▁The ▁study ▁was ▁prem ature ly ▁terminated , ▁and ▁the ▁reason ▁remains ▁unclear . ▁However , ▁San of i ▁has ▁since ▁dis cont in ued ▁its ▁development . ▁The ▁company ▁announced ▁in ▁May ▁ 2 0 1 1 ▁that ▁the ▁drug ▁is ▁available ▁for ▁lic ens ing . ▁A ▁system atic ▁review ▁found ▁that ▁until ▁now ▁there ▁is ▁not ▁sufficient ▁evidence ▁to ▁clarify ▁whether ▁id ra par in ux ▁or ▁id rab iot ap arin ux ▁are ▁as ▁effective ▁and ▁safe ▁as ▁the ▁standard ▁war far in ▁treatment ▁for ▁ven ous ▁th rom bo emb ol ism ▁prevent ion . ▁Id ra par in ux ▁or ▁id rab iot ap arin ux ▁decre ased ▁major ▁ble eding ▁rate ▁significantly ▁but ▁had ▁a ▁tr end ▁to ▁increase ▁the ▁all - c ause ▁mort ality ▁compared ▁with ▁war far in . ▁ ▁References ▁ ▁Category : O